1. Home
  2. SKYE vs WHF Comparison

SKYE vs WHF Comparison

Compare SKYE & WHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$0.62

Market Cap

44.9M

Sector

Health Care

ML Signal

HOLD

WHF

WhiteHorse Finance Inc.

HOLD

Current Price

$7.32

Market Cap

157.2M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
SKYE
WHF
Founded
2012
2011
Country
United States
United States
Employees
N/A
3
Industry
Biotechnology: Pharmaceutical Preparations
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
44.9M
157.2M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
SKYE
WHF
Price
$0.62
$7.32
Analyst Decision
Strong Buy
Sell
Analyst Count
4
2
Target Price
$14.75
$7.75
AVG Volume (30 Days)
286.5K
122.7K
Earning Date
03-10-2026
03-02-2026
Dividend Yield
N/A
14.68%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$15.35
Revenue Growth
N/A
N/A
52 Week Low
$0.62
$6.07
52 Week High
$5.75
$9.95

Technical Indicators

Market Signals
Indicator
SKYE
WHF
Relative Strength Index (RSI) 36.73 59.38
Support Level N/A $6.79
Resistance Level $0.83 $7.73
Average True Range (ATR) 0.05 0.22
MACD -0.00 -0.01
Stochastic Oscillator 4.28 59.75

Price Performance

Historical Comparison
SKYE
WHF

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About WHF WhiteHorse Finance Inc.

WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.

Share on Social Networks: